Cardiovascular companies develop diagnostics, therapies and research technologies for diseases affecting the heart and circulatory system. Their work supports earlier detection, improved disease management and the development of new treatments for cardiovascular conditions.
This category includes companies working on:
Browse 71 UK cardiovascular companies below.
Stabilised siRNA therapeutics platform targeting cardiovascular gene silencing
Argonaute RNA is a biopharmaceutical company developing small interfering RNA therapeutics for cardiovascular disease. Its siRNA platform uses proprietary chemical stabilisation to enable safe, targeted and temporary gene silencing in specific tissue cells, overcoming delivery and safety barriers that have constrained…
Cell therapy for vascular regeneration in ischaemic and wound healing conditions
VascVersa is a Belfast-based regenerative medicine company developing cell therapies for vascular regeneration and repair. The company's technology uses vasoreparative cells to stimulate new blood vessel formation and restore blood supply in conditions characterised by impaired circulation. The lead programme targets…
AI and multi-omics platform for cardiovascular drug target discovery
CardiaTec Biosciences is a Cambridge-based biotech applying artificial intelligence to large-scale multi-omic data to identify novel drug targets for cardiovascular diseases. Its platform integrates data across genomic, epigenomic, transcriptomic, proteomic and metabolomic layers to map disease mechanisms and uncover…
Preclinical cardioprotective proteins for heart attack treatment
Forcefield Therapeutics is a preclinical biotechnology company developing cardioprotective protein therapies for acute myocardial infarction. Its programme uses naturally occurring proteins identified through the FunSel discovery platform to protect cardiomyocytes after a heart attack, reduce tissue damage and…
Mitochondrial transplantation platform to restore cellular energy and regeneration
Recondria Therapeutics is a developer of a mitochondrial transplantation platform designed to restore cellular energy, accelerate tissue recovery and support regenerative medicine. The company's approach involves isolating healthy mitochondria and delivering them to damaged cells to restore ATP production and cellular…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
High-density e-textile sensors for AI-powered cardiac diagnostics
Polytecks is a University of Cambridge spin-out developing wearable, textile-based sensors for high-resolution bioelectrical mapping. Patented electrode arrays capture heart signals at far higher density than standard ECGs, with AI transforming the data into detailed cardiac maps within minutes to support earlier…
High-affinity sheep monoclonal antibodies for clinical diagnostic testing
Bioventix is a UK biotechnology company that creates, manufactures and supplies high-affinity sheep monoclonal antibodies for clinical diagnostic applications, particularly where conventional antibodies have failed to detect low-concentration or difficult targets. Its antibodies are supplied to major multinational in…
Independent global health research institute focused on chronic diseases
The George Institute for Global Health (UK) is an independent medical research institute conducting large-scale clinical trials, population studies, and health policy research on non-communicable diseases. Based at Imperial College London's White City Campus and affiliated with Imperial as a strategic partner, the UK…
Point-of-care pharmacogenetic testing platform for emergency healthcare
Genedrive is a molecular diagnostics company developing point-of-need pharmacogenetic tests that identify genetic variants to guide safer, more personalised medicine decisions in time-critical emergency care. Its flagship products, developed and validated with NHS partners, include a neonatal test preventing…
Predictive genetic tests for cancer and cardiovascular disease
GENinCode is a clinical-stage diagnostics company developing polygenic risk assessment tests for cardiovascular disease and ovarian cancer. Its portfolio includes CE-marked molecular tests for coronary artery disease, familial hypercholesterolaemia and thrombosis risk, alongside the ROCA test for ovarian cancer…